Using an AI-Assisted Mobile App to Guide Early Thrombolysis and Treatment in Adults With ST-Elevation Myocardial Infarction STEMI

What this Trial Is About

This research aims to evaluate whether using a new artificial intelligence assisted mobile application can improve clinical outcomes for patients with ST-elevation myocardial infarction STEMI who have difficulty passing a guide wire through the lesion within 120 minutes after diagnosis. The study addresses concerns about the inadequate use of thrombolysis in STEMI patients in China by applying this AI tool to guide thrombolysis combined with PCI treatment. It seeks to enhance rapid coordination across medical networks, increase early thrombolysis use before hospital arrival, shorten time to reperfusion, and provide a reliable strategy to optimize early reperfusion. The study includes two groups an experimental group using the AI-assisted mobile application to guide the entire reperfusion process, including patient screening, education, route planning, time management, and quality control and a control group managed according to existing treatment models. The thrombolytic drug used is tenecteplase. The trial is a multi-center cluster randomized controlled design comparing these approaches. Participants will be monitored for major adverse events at one year, with additional measures including total ischemic time before reperfusion, reperfusion rates within 48 hours, ECG ST segment resolution, TIMI blood flow grades before and after emergency PCI, and incidence of cardiac events at 30 days and one year. The study runs until July 2029 and involves regular assessments and data collection to track outcomes and treatment quality in both groups.

Early Thrombolysis Guided by AI-Assisted App in Patients With STEMI